The inconvenience of convenience cohorts: Rhabdomyosarcoma and the PAX-FOXO1 biomarker

Cancer Epidemiology Biomarkers and Prevention

Volumn 21, Issue 7, 2012, Pages 1012-1018

  Rosenberg, Abby R ^a,b,c   Skapek, Stephen X ^d   Hawkins, Douglas S ^a,b,c  

^a SEATTLE CHILDREN S HOSPITAL   (United States)

^b USA   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; TRANSCRIPTION FACTOR FKHR; TRANSCRIPTION FACTOR PAX3; TRANSCRIPTION FACTOR PAX7;

CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; COHORT ANALYSIS; COMPARATIVE STUDY; EVENT FREE SURVIVAL; HUMAN; METASTASIS; OVERALL SURVIVAL; PHENOTYPE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; RHABDOMYOSARCOMA;

CHILD; CLINICAL TRIALS AS TOPIC; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; PATIENT SELECTION; PAX7 TRANSCRIPTION FACTOR; RHABDOMYOSARCOMA; TUMOR MARKERS, BIOLOGICAL;

EID: 84863564132     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-12-0207     Document Type: Review

References (27)

1. Petrie A, Sabin C. Medical statistics at a glance. Oxford: Blackwell Science, Ltd.; 2000.
2. Sudman S. Applied sampling. New York: Academic Press; 1976.
3. Ries LAG, Smith MA, Gurney JG, Linet M, Tamra T, Young JL, et al. Cancer incidence and survival among children and adolescents: United States SEER Program 1975-1995. Bethesda, MD: National Cancer Institute; 1999 [cited 2012 Feb 7]; Available from: seer.cancer.gov/publications/childhood/softtissue.pdf.
4. Meza JL, Anderson J, Pappo AS, Meyer WH. Analysis of prognostic factors in patients with nonmetastatic rhabdomyosarcoma treated on intergroup rhabdomyosarcoma studies III and IV: the Children's Oncology Group. J Clin Oncol 2006;24:3844-51. (Pubitemid 46630730)
5. Raney RB, Anderson JR, Barr FG, Donaldson SS, Pappo AS, Qualman SJ, et al. Rhabdomyosarcoma and undifferentiated sarcoma in the first two decades of life: a selective review of intergroup rhabdomyosarcoma study group experience and rationale for Intergroup Rhabdomyosarcoma Study V. J Pediatr Hematol Oncol 2001;23:215-20. (Pubitemid 32524925)
6. Oberlin O, Rey A, Lyden E, Bisogno G, Stevens MC, Meyer WH, et al. Prognostic factors in metastatic rhabdomyosarcomas: results of a pooled analysis from United States and European cooperative groups. J Clin Oncol 2008;26:2384-9.
7. Sorensen PH, Lynch JC, Qualman SJ, Tirabosco R, Lim JF, Maurer HM, et al. PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the children's oncology group. J Clin Oncol 2002;20:2672-9. (Pubitemid 34575640)
8. Williamson D, Missiaglia E, de Reynies A, Pierron G, Thuille B, Palenzuela G, et al. Fusion gene-negative alveolar rhabdomyosarcoma is clinically and molecularly indistinguishable from embryonal rhabdomyosarcoma. J Clin Oncol 2010;28:2151-8.
9. Dumont SN, Lazar AJ, Bridge JA, Benjamin RS, Trent JC. PAX3/7-FOXO1 fusion status in older rhabdomyosarcoma patient population by fluorescent in situ hybridization. J Cancer Res Clin Oncol 2012;138:213-20.
10. Barr FG. Chromosomal translocations involving paired box transcription factors in human cancer. Int J Biochem Cell Biol 1997;29:1449-61. (Pubitemid 28153493)
11. Douglass EC, Rowe ST, Valentine M, Parham DM, Berkow R, Bowman WP, et al. Variant translocations of chromosome 13 in alveolar rhabdomyosarcoma. Genes Chromosomes Cancer 1991;3:480-2.
12. Galili N, Davis RJ, Fredericks WJ, Mukhopadhyay S, Rauscher FJ III, Emanuel BS, et al. Fusion of a fork head domain gene to PAX3 in the solid tumour alveolar rhabdomyosarcoma. Nat Genet 1993;5:230-5. (Pubitemid 23330384)
13. Barr FG. Gene fusions involving PAX and FOX family members in alveolar rhabdomyosarcoma. Oncogene 2001;20:5736-46. (Pubitemid 32928111)
14. Barr FG, Galili N, Holick J, Biegel JA, Rovera G, Emanuel BS. Rearrangement of the PAX3 paired box gene in the paediatric solid tumour alveolar rhabdomyosarcoma. Nat Genet 1993;3:113-7. (Pubitemid 23079791)
15. Kelly KM, Womer RB, Sorensen PH, Xiong QB, Barr FG. Common and variant gene fusions predict distinct clinical phenotypes in rhabdomyosarcoma. J Clin Oncol 1997;15:1831-6. (Pubitemid 27209511)
16. Anderson J, Gordon T, McManus A, Mapp T, Gould S, Kelsey A, et al. Detection of the PAX3-FKHR fusion gene in paediatric rhabdomyosarcoma: a reproducible predictor of outcome? Br J Cancer 2001;85:831-5. (Pubitemid 33010549)
17. Barr FG, Smith LM, Lynch JC, Strzelecki D, Parham DM, Qualman SJ, et al. Examination of gene fusion status in archival samples of alveolar rhabdomyosarcoma entered on the Intergroup Rhabdomyosarcoma Study-III trial: a report from the Children's Oncology Group. J Mol Diagn 2006;8:202-8. (Pubitemid 43811243)
18. Stegmaier S, Poremba C, Schaefer KL, Leuschner I, Kazanowska B, Bekassy AN, et al. Prognostic value of PAX-FKHR fusion status in alveolar rhabdomyosarcoma: a report from the cooperative soft tissue sarcoma study group (CWS). Pediatr Blood Cancer 2011;57:406-14.
19. Wexler LH, Ladanyi M. Diagnosing alveolar rhabdomyosarcoma: morphology must be coupled with fusion confirmation. J Clin Oncol 2010;28:2126-8.
20. Lae M, Ahn EH, Mercado GE, Chuai S, Edgar M, Pawel BR, et al. Global gene expression profiling of PAX-FKHR fusion-positive alveolar and PAX-FKHR fusion-negative embryonal rhabdomyosarcomas. J Pathol 2007;212:143-51. (Pubitemid 46852092)
21. Biegel JA, Meek RS, Parmiter AH, Conard K, Emanuel BS. Chromosomal translocation t(1;13)(p36;q14) in a case of rhabdomyosarcoma. Genes Chromosomes Cancer 1991;3:483-4.
22. Douglass EC, Shapiro DN, Valentine M, Rowe ST, Carroll AJ, Raney RB, et al. Alveolar rhabdomyosarcoma with the t(2;13): cytogenetic findings and clinicopathologic correlations. Med Pediatr Oncol 1993;21:83-7. (Pubitemid 23029850)
23. Baker KS, Anderson JR, Link MP, Grier HE, Qualman SJ, Maurer HM, et al. Benefit of intensified therapy for patients with local or regional embryonal rhabdomyosarcoma: results from the Intergroup Rhabdomyosarcoma Study IV. J Clin Oncol 2000;18:2427-34. (Pubitemid 30415830)
24. Crist WM, Anderson JR, Meza JL, Fryer C, Raney RB, Ruymann FB, et al. Intergroup rhabdomyosarcoma study-IV: results for patients with nonmetastatic disease. J Clin Oncol 2001;19:3091-102. (Pubitemid 32567502)
25. Breneman JC, Lyden E, Pappo AS, Link MP, Anderson JR, Parham DM, et al. Prognostic factors and clinical outcomes in children and adolescents with metastatic rhabdomyosarcoma - a report from the Intergroup Rhabdomyosarcoma Study IV. J Clin Oncol 2003;21:78-84.
26. Crist W, Gehan EA, Ragab AH, Dickman PS, Donaldson SS, Fryer C, et al. The third intergroup rhabdomyosarcoma study. J Clin Oncol 1995;13:610-30.
27. Anderson JR, Barr FG, Hawkins DS, Parham DM, Skapek SX, Triche TJ. Fusion-negative alveolar rhabdomyosarcoma: modification of risk stratification is premature. J Clin Oncol 2010;28:e587-8; author reply e589-90.